BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gunaratne AW, Hamblin H, Clancy A, Magat AJMC, Dawson MVM, Tu J, Borody TJ. Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections-Exploratory study. Helicobacter 2021;:e12830. [PMID: 34247436 DOI: 10.1111/hel.12830] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Seicean R. Vonoprazan Versus Conventional Proton Pump Inhibitor in the Therapeutic Armamentarium of Peptic Ulcer Disease and Gastroesophageal Reflux Disease. Peptic Ulcer Disease - What's New? 2022. [DOI: 10.5772/intechopen.101349] [Reference Citation Analysis]
2 Hu Y, Xu X, Ouyang Y, He C, Li N, Xie C, Peng C, Zhu Z, Xie Y, Shu X, Lu N, Zhu Y. Optimization of vonoprazan‐amoxicillin dual therapy for eradicating Helicobacter pylori infection in China: A prospective, randomized clinical pilot study. Helicobacter. [DOI: 10.1111/hel.12896] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Mladenova I. Clinical Relevance of Helicobacter pylori Infection. J Clin Med 2021;10:3473. [PMID: 34441769 DOI: 10.3390/jcm10163473] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 15.0] [Reference Citation Analysis]